{"title":"Actualité sur la maladie de Still de l’enfant et de l’adulte","authors":"Bruno Fautrel , Stéphane Mitrovic","doi":"10.1016/j.rhum.2026.01.027","DOIUrl":"10.1016/j.rhum.2026.01.027","url":null,"abstract":"<div><div>L’arthrite juvénile idiopathique systémique (FS-AJI) et la maladie de Still de l’adulte (MSA) sont considérées comme une seule et même maladie, mais il n’existe toujours pas d’approche commune pour leur diagnostic et leur prise en charge. En 2024, l’EULAR et le PReS ont endossé les premières recommandations pour le diagnostic et la prise en charge de la maladie de Still. Ce travail a débuté par la formulation de quatre principes généraux, avec l’affirmation du caractère unique de la maladie, qui doit désormais être désignée par un seul nom, maladie de Still. Quatorze recommandations spécifiques ont été émises. Deux objectifs thérapeutiques ont été définis : la maladie cliniquement inactive (MCI) et la rémission, c’est-à-dire une MCI maintenue pendant au moins 6 mois. La stratégie thérapeutique optimale repose sur l’utilisation précoce d’inhibiteurs de l’IL-1 ou de l’IL-6 associés à une corticothérapie de courte durée (GC). Le traitement de la MAS doit reposer sur des GC à forte dose, des inhibiteurs de l’IL-1, de la ciclosporine et/ou des inhibiteurs de l’IFNγ. Une préoccupation spécifique a récemment été soulevée concernant les cas de maladie pulmonaire grave chez les enfants atteints de la maladie de Still, pour lesquels des immunosuppresseurs dirigés contre les lymphocytes T sont suggérés. Les recommandations ont souligné le rôle clé des centres spécialisés pour les patients difficiles à traiter. Ces recommandations constituent le premier consensus sur le diagnostic et la prise en charge des enfants et des adultes atteints de la maladie de Still.</div></div><div><div>Systemic juvenile idiopathic arthritis (SJIA) and adult Still's disease (ASD) are considered to be one and the same disease, but there is still no common approach to their diagnosis and management. In 2024, EULAR and PReS endorsed the first recommendations for the diagnosis and management of Still's disease. This work began with the formulation of four general principles, affirming the unique nature of the disease, which should now be referred to by a single name, Still's disease. Fourteen specific recommendations were issued. Two therapeutic goals were defined: clinically inactive disease (CID) and remission, i.e., sustained CID for at least 6 months. The optimal therapeutic strategy is based on the early use of IL-1 or IL-6 inhibitors combined with short-term corticosteroid therapy (GC). Treatment of SJS should be based on high-dose GC, IL-1 inhibitors, cyclosporine, and/or IFNγ inhibitors. A specific concern has recently been raised regarding cases of severe lung disease in children with Still's disease, for whom T-cell-directed immunosuppressants are suggested. The recommendations emphasized the key role of specialized centers for difficult-to-treat patients. These recommendations represent the first consensus on the diagnosis and management of children and adults with Still's disease.</div></div>","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"93 3","pages":"Pages 343-350"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147961187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Traitement médical de la radiculalgie sur hernie discale","authors":"Arthur Dollinger","doi":"10.1016/j.rhum.2026.01.025","DOIUrl":"10.1016/j.rhum.2026.01.025","url":null,"abstract":"","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"93 2","pages":"Pages 266-267"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147416512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Regards croisés sur la maladie de Still","authors":"Mayalen Uthurriague","doi":"10.1016/j.rhum.2026.01.020","DOIUrl":"10.1016/j.rhum.2026.01.020","url":null,"abstract":"","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"93 2","pages":"Page 302"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147416857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"La consultation préconceptionnelle chez les patientes atteintes de maladies immuno-médiées","authors":"Agnès Martin , Emmanuelle Vignot","doi":"10.1016/j.rhum.2025.10.487","DOIUrl":"10.1016/j.rhum.2025.10.487","url":null,"abstract":"<div><div>Les maladies auto-immunes systémiques sont majoritairement présentes chez les femmes en âge de procréer. Ainsi, la grossesse est importante à évoquer précocement lors de la prise en charge puisque la plupart des thérapies de première ligne sont tératogènes. De ce fait, il est important pour le rhumatologue de programmer la conception avec la patiente, de s’assurer du contrôle de la maladie, et de prendre en considération les traitements en cours. Si le traitement est tératogène (comme le méthotrexate), il devra être remplacé par une autre thérapie. Selon la pathologie, pourront se discuter les glucocorticoïdes, la sulfasalazine, le tacrolimus, l’hydroxychloroquine ou les biothérapies anti-TNF. Le rhumatologue devra également prendre en considération le profil immunologique de la patiente avant la grossesse et rechercher particulièrement les anticorps anti-SSA/SSB et les antiphospholipides dans le but de prévenir la survenue d’un lupus néonatal ou d’évènements thrombotiques. Enfin, comme pour toute grossesse, il conviendra de discuter avec la patiente de son mode de vie (tabagisme, consommation d’alcool, alimentation, et dépistage des cancers).</div></div><div><div>Immune-mediated inflammatory diseases are mainly observed in young women. In this context, pregnancy is a major concern because most first-line therapies are toxic to the fetus. Therefore, it is important for the rheumatologist to plan conception, to ensure disease control beforehand, and to take into account the current treatment. If the treatment is toxic (such as methotrexate), it should be switched to another therapy (such as glucocorticoids, sulfasalazine, tacrolimus, hydroxychloroquine, or TNF inhibitors). The rheumatologist should also assess the immune profile before pregnancy and test for anti-SSA/SSB antibodies and antiphospholipid antibodies in order to prevent neonatal lupus and thrombosis. Finally, as in any pregnancy, it is also useful to discuss lifestyle factors (smoking, alcohol consumption, nutrition, and cancer screening).</div></div>","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"93 2","pages":"Pages 206-211"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147416507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Point de vue : les T-cell engagers, une nouvelle ère pour la déplétion B","authors":"Baptiste Chevet","doi":"10.1016/j.rhum.2026.01.009","DOIUrl":"10.1016/j.rhum.2026.01.009","url":null,"abstract":"","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"93 2","pages":"Pages 303-304"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147416856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pièges diagnostiques en imagerie ostéoarticulaire chez l’adulte... en 6 cas cliniques","authors":"Arthur Dollinger","doi":"10.1016/j.rhum.2026.01.024","DOIUrl":"10.1016/j.rhum.2026.01.024","url":null,"abstract":"","PeriodicalId":38943,"journal":{"name":"Revue du Rhumatisme (Edition Francaise)","volume":"93 2","pages":"Pages 270-276"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147416514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}